Bolarin D M, Savolainen E R, Kivirikko K I
Int J Cancer. 1982 Apr 15;29(4):401-5. doi: 10.1002/ijc.2910290407.
Serum immunoreactive prolyl hydroxylase protein (S-IRPH), galactosylhydroxylysyl glucosyltransferase activity (S-GGT) and the amino-terminal propeptide of type III procollagen [S-Pro(III)-N-P] were studied in 24 patients with primary hepatocellular carcinoma, 18 with secondary liver neoplasms and 35 with other malignant diseases but no evidence of liver involvement; this latter group included 13 patients with Burkitt's lymphoma, 11 with breast cancer and 11 with other neoplasms. Control values were determined for 60 apparently healthy Nigerians, S-IRPH and S-GGT were above the upper normal limit, defined as the mean + 2 SD of the controls, in all the patients with primary hepatocellular carcinoma and all but one with secondary liver neoplasms, whereas only one S-IRPH value and three S-GGT values exceeded this limit in the patients with other malignant diseases. The mean S-Pro(III)-N-P was even more elevated than S-IRPH and S-GGT in the primary and secondary liver neoplasm cases, but was also elevated in other malignant neoplasms; about one third of the patients with no evidence of liver involvement had a concentration exceeding the upper normal limit. A high correlation was found between the values for the three assays both in primary hepatocellular carcinoma and in the whole series of malignant diseases. The data suggest that primary and secondary malignant neoplasms of the liver have a high rate of collagen synthesis. The three assays may be of some value in the diagnosis of primary hepatocellular carcinoma and secondary liver involvement in other malignant diseases, and in monitoring the treatment provided.
对24例原发性肝细胞癌患者、18例继发性肝肿瘤患者以及35例患有其他恶性疾病但无肝脏受累证据的患者(后一组包括13例伯基特淋巴瘤患者、11例乳腺癌患者和11例其他肿瘤患者)进行了血清免疫反应性脯氨酰羟化酶蛋白(S-IRPH)、半乳糖基羟赖氨酰葡糖基转移酶活性(S-GGT)以及III型前胶原氨基端前肽[S-Pro(III)-N-P]的研究。测定了60名表面健康的尼日利亚人的对照值。在所有原发性肝细胞癌患者以及除1例之外的所有继发性肝肿瘤患者中,S-IRPH和S-GGT均高于正常上限,正常上限定义为对照值的均值+2个标准差,而在患有其他恶性疾病的患者中,只有1个S-IRPH值和3个S-GGT值超过该上限。在原发性和继发性肝肿瘤病例中,S-Pro(III)-N-P的均值甚至比S-IRPH和S-GGT升高得更多,但在其他恶性肿瘤中也升高;在无肝脏受累证据的患者中,约三分之一的患者浓度超过正常上限。在原发性肝细胞癌以及整个恶性疾病系列中,三种检测方法的值之间均发现高度相关。数据表明,肝脏的原发性和继发性恶性肿瘤具有较高的胶原合成率。这三种检测方法在原发性肝细胞癌的诊断、其他恶性疾病中继发性肝脏受累的诊断以及监测所提供的治疗方面可能具有一定价值。